Advances in surgical treatment of ovarian cancer liver metastasis


  • Zhang Zhiqiong Department of Obstetrics and Gynecology, Jiangjin Maternal and Child Health Hospital, Chongqing, China
  • Wu Xinglang Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
  • Gong Jianping Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China



Ovarian cancer, Liver metastasis, Surgical treatment, Cytoreductive surgery, Review


Ovarian cancer (OC) is one of the most common gynecological malignancies with characteristics of insidious onset and liver is the most common solid metastatic organ. Surgical treatment for newly diagnosed advanced or recurrent ovarian cancer liver metastasis has become a research hotspot as good outcome of patients with liver metastasis from colorectal cancer or neuroendocrine tumor by surgical treatment. It was previously considered that such patients were advanced and unfavourable for surgical treatment. However, in recent years, with the advances in liver surgical techniques, the application of three-dimensional visualization and the rise of multidisciplinary diagnosis and treatment mode, the safety of surgery has been guaranteed and the prognosis has been improved. This article reviewed the advances in surgical treatment of ovarian cancer liver metastasis.


Kurman RJ, Shih I. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433-43.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49.

Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284-96.

Prat J. Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum. Cancer. 2015;121(19):3452-4.

Tokunaga H, Mikami M, Nagase S, Kobayashi Y, Tabata T, Kaneuchi M, et al. The 2020 Japan society of gynecologic oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. J Gynecol Oncol. 2021;32(2):49.

Ataseven B, Chiva LM, Harter P, Gonzalez-Martin A, duBois A. FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited. Gynecol Oncol. 2016;142(3):597-607.

Gardner AB, Charo LM, Mann AK, Kapp DS, Eskander RN, Chan JK. Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes. Clin Exp Metastas. 2020;37(1):107-13.

Chi DS, Fong Y, Venkatraman ES, Barakat RR. Hepatic resection for metastatic gynecologic carcinomas. Gynecol Oncol. 1997;66(1):45-51.

Deng K, Yang C, Tan Q, Song W, Lu M, Zhao W, et al. Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients. Gynecol Oncol. 2018;150(3):460-5.

Bacalbaşa N, Balescu I, Dima S, Popescu I. Long-term survivors after liver resection for ovarian cancer liver metastases. Anticancer Res. 2015;35(12):6919-23.

Neumann UP, Fotopoulou C, Schmeding M, Thelen A, Papanikolaou G, Braicu EI, et al. Clinical outcome of patients with advanced ovarian cancer after resection of liver metastases. Anticancer Res. 2012;32(10):4517-21.

Gasparri ML, Grandi G, Bolla D, Gloor B, Imboden S, Panici PB, et al. Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. J Cancer Res Clin Oncol. 2016;142(7):1509-20.

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(2):191-226.

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248-59.

Nakayama K, Nakayama N, Katagiri H, Miyazaki K. Mechanisms of ovarian cancer metastasis: biochemical pathways. Int J Mol Sci. 2012;13(9):11705-17.

Wang M, Zhou J, Zhang L, Zhao Y, Zhang N, Wang L, et al. Surgical treatment of ovarian cancer liver metastasis. Hepatobil Surg Nutr. 2019;8(2):129-37.

Zivanovic O, Eisenhauer EL, Zhou Q, Iasonos A, Sabbatini P, Sonoda Y, et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2008;108(2):287-92.

Eisenhauer EL, Chi DS. Liver mobilization and diaphragm peritonectomy/resection. Gynecol Oncol. 2007;104:25-8.

Einenkel J, Ott R, Handzel R, Braumann UD, Horn LC. Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian, fallopian tube, or peritoneal cancer. Int J Gynecol Cancer. 2009;19(7):1288-97.

Winter WE, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2008;26(1):83-9.

Gallotta V, Ferrandina G, Vizzielli G, Conte C, Lucidi A, Costantini B, et al. Hepatoceliac lymph node involvement in advanced ovarian cancer patients: prognostic role and clinical considerations. Ann Surg Oncol. 2017;24(11):3413-21.

Zhang L, Yu X, Wei W, Pan X, Lu L, Xia J, et al. Prediction of HCC microvascular invasion with gadobenate-enhanced MRI: correlation with pathology. Eur Radiol. 2020;30(10):5327-36.

Li P, Wang M, Yang Y, Liu H, Pan Z, Jiang B, et al. Preoperative three-dimensional versus two-dimensional evaluation in assessment of patients undergoing major liver resection for hepatocellular carcinoma: a propensity score matching study. Ann Transl Med. 2020;8(5):182.

Fang C, An J, Bruno A, Cai X, Fan J, Fujimoto J, et al. Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases. Hepatol Int. 2020;14(4):437-53.

Hanprasertpong J, Fujiwara K. Splenectomy and surgical cytoreduction in epithelial ovarian cancer: a review. Eur J Cancer Care (Engl). 2011;20(3):287-93.

Goodenough CJ, Liang MK, Nguyen MT, Nguyen DH, Holihan JL, Alawadi ZM, et al. Preoperative glycosylated hemoglobin and postoperative glucose together predict major complications after abdominal surgery. J Am Coll Surgeons. 2015;221(4):854-61.

Chedid MF, Kruel CRP, Pinto MA, Grezzana-Filho TJM, Leipnitz I, Kruel CDP, et al. Hepatocellular carcinoma: diagnosis and operative management. Arq Bras Cir Dig. 2017;30(4):272-8.

Ross SW, Seshadri R, Walters AL, Augenstein VA, Heniford BT, Iannitti DA, et al. Mortality in hepatectomy: model for end-stage liver disease as a predictor of death using the national surgical quality improvement program database. Surgery. 2016;159(3):777-92.

Yao LQ, Yuan L, Hua KQ. Surgical tretment of metastatic ovarian cancer in the upper abdomen. Chin J Metastatic Cancer. 2020;3(4):247-51.

Yang LY, Xu JF. Surgical management of hepatic metastases of ovarian carcinoma. Chin J Practical Surg. 2011;(11):1019-21.

Elies A, Rivière S, Pouget N, Becette V, Dubot C, Donnadieu A, et al. The role of neoadjuvant chemotherapy in ovarian cancer. Expert Rev Anticancer Ther. 2018;18(6):555-66.

Driel WJ, Koole SN, Sikorska K, Leeuwen JHSV, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230-40.

Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570-5.

Liu B, Huang G, Jiang C, Xu M, Zhuang B, Lin M, et al. Ultrasound-guided percutaneous radiofrequency ablation of liver metastasis from ovarian cancer: a single-center initial experience. Int J Gynecol Cancer. 2017;27(6):1261-7.

Vogl TJ, Naguib NN, Lehnert T, Nour-Eldin NE, Eichler K, Zangos S, et al. Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: indications, outcomes and role in patient's management. Gynecol Oncol. 2012;124(2):225-9.

Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473-83.

Kaye SB. Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years. Ann Oncol. 2016;27(1):1-3.

Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495-505.






Review Articles